Exelixis Inc Capital Expenditures Incurred but Not yet Paid
Exelixis Inc (EXEL) reported Capital Expenditures Incurred but Not yet Paid of $1.64 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-01.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2022-11-01
- Exelixis Inc capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was -$1.93M, a 10805.56% decline year-over-year.
- Exelixis Inc capital expenditures incurred but not yet paid for the quarter ending 2021-12-31 was -$2.40M.
- Exelixis Inc capital expenditures incurred but not yet paid for the quarter ending 2021-10-01 was $18.00K, a 53.85% decline year-over-year.
- Exelixis Inc capital expenditures incurred but not yet paid for the quarter ending 2021-01-01 was -$1.00K.
- Exelixis Inc capital expenditures incurred but not yet paid for fiscal 2021 was $2.74M, a 225.30% increase from fiscal 2021.
- Exelixis Inc capital expenditures incurred but not yet paid for fiscal 2021 was $842.00K, a 3138.46% increase from fiscal 2020.
- Exelixis Inc capital expenditures incurred but not yet paid for fiscal 2020 was $26.00K, a 96.76% decline from fiscal 2018.
- Exelixis Inc capital expenditures incurred but not yet paid for fiscal 2018 was $802.00K, a 53.05% increase from fiscal 2017.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $1.64M 10-Q · filed 2022-11-01 | ||
| 2022-07-01 | $3.57M 10-Q · filed 2022-08-09 | |||
| 2021-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$2.39M derived: sum of 2 quarters · filed 2022-11-01 | $2.74M 10-K · filed 2022-02-18 | |
| 2021-10-01 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $5.14M 10-Q · filed 2022-11-01 | ||
| 2021-07-02 | $5.13M 10-Q · filed 2022-08-09 | |||
| 2021-01-01 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $38.00K derived: sum of 2 quarters · filed 2022-02-18 | $361.00K derived: sum of 3 quarters · filed 2022-02-18 | $842.00K 10-K · filed 2022-02-18 |
| 2020-10-02 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $362.00K derived: sum of 2 quarters · filed 2021-11-02 | $843.00K 10-Q · filed 2021-11-02 | $710.00K derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | $323.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $804.00K 10-Q · filed 2021-08-05 | $671.00K derived: sum of 3 quarters · filed 2022-02-18 | -$520.00K derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | $481.00K 10-Q · filed 2020-05-05 | $348.00K derived: sum of 2 quarters · filed 2022-02-18 | -$843.00K derived: sum of 3 quarters · filed 2022-02-18 | $366.00K derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-01-03 | -$133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$1.32M derived: sum of 2 quarters · filed 2022-02-18 | -$115.00K derived: sum of 3 quarters · filed 2022-02-18 | $26.00K 10-K · filed 2022-02-18 |
| 2019-09-27 | -$1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $18.00K derived: sum of 2 quarters · filed 2020-11-05 | $159.00K 10-Q · filed 2020-11-05 | -$320.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-28 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.35M 10-Q · filed 2020-08-06 | $871.00K derived: sum of 3 quarters · filed 2020-08-06 | -$11.82M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-29 | $141.00K 10-Q · filed 2020-05-05 | -$338.00K derived: sum of 2 quarters · filed 2020-05-05 | -$13.03M derived: sum of 3 quarters · filed 2020-05-05 | -$5.67M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-28 | -$479.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$13.17M derived: sum of 2 quarters · filed 2020-02-25 | -$5.81M derived: sum of 3 quarters · filed 2020-02-25 | $802.00K 10-K · filed 2021-02-11 |
| 2018-09-28 | -$12.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | -$5.33M derived: sum of 2 quarters · filed 2019-10-30 | $1.28M 10-Q · filed 2019-10-30 | $1.56M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-29 | $7.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $13.97M 10-Q · filed 2019-07-31 | $14.25M derived: sum of 3 quarters · filed 2020-02-25 | $13.96M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-30 | $6.61M 10-Q · filed 2019-05-01 | $6.89M derived: sum of 2 quarters · filed 2020-02-25 | $6.60M derived: sum of 3 quarters · filed 2020-02-25 | |
| 2017-12-29 | $279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$7.00K derived: sum of 2 quarters · filed 2020-02-25 | $524.00K 10-K · filed 2020-02-25 | |
| 2017-09-29 | -$286.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $245.00K 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | $531.00K 10-Q · filed 2018-08-01 | |||
| 2016-12-30 | $0.00 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |